Jump to a section
- What is TB-500?
- Why researchers study it
- Benefits discussed in literature
- Uses discussed in research
- Mechanisms discussed in published studies
- Reported study designs and protocol examples
- Protocol table from cited sources
- Limitations and research gaps
- Documentation checklist
- Related research supplies
- More TB-500 research
- Sources and references
Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.
This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.
Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.
This article summarizes what peer-reviewed sources report about TB-500 (a synthetic fragment of thymosin β4): its biochemical identity, why it has been studied, benefits and uses described in the literature, mechanistic notes, and examples of reported experimental protocols. Coverage is based only on the provided reviewed source excerpts and highlights evidence gaps.
What is TB-500?
TB-500 is a synthetic peptide corresponding to a short active region of thymosin β4 (sequence LKKTETQ with an N‑acetylated N‑terminus in many preparations) that has been described as an actin‑binding segment and as an active site responsible for cell migration and wound‑healing properties of thymosin β4. [S8] [S4]
Literature reviews list TB‑500 among wound‑healing peptides and characterize it as a peptide investigated for effects on angiogenesis, extracellular matrix remodeling, and skin or dermal repair. [S1] [S3]
Why researchers study it
Researchers have studied TB‑500 because it is thought to influence processes relevant to tissue repair — including angiogenesis, cell migration, actin dynamics, and extracellular matrix remodeling — making it of interest for orthopaedic, wound‑healing, and aging research contexts. [S1] [S4] [S5]
Reviews emphasize growing interest in therapeutic peptides for regenerative medicine but also note a paucity of human clinical trials and limited human safety data for many investigational peptides including TB‑500. [S1] [S2] [S3] [S5]
Benefits discussed in literature
Preclinical and analytical studies describe TB‑500 or its fragment as associated with wound‑healing–related activities such as promotion of angiogenesis, keratinocyte migration, actin binding, and dermal repair in experimental systems. [S8] [S4] [S1]
An exploratory rat tendon repair study reported that TB‑500 treatment was associated with improved histopathological parameters and extracellular matrix organization and produced a statistically significant increase in maximum load‑to‑failure versus control at four weeks in that model. [S7]
Analytical work on metabolism indicates some TB‑500 metabolites (for example Ac‑LKKTE) exhibited measurable wound‑healing activity in fibroblast wound‑healing assays, suggesting metabolite contributions to observed biological effects. [S4]
Multiple reviews caution that most positive findings for TB‑500 are from preclinical or analytical studies and that human clinical evidence supporting safety or efficacy is lacking. [S2] [S3] [S1]
TB‑500 (and related thymosin β4 preparations) have been discussed in the sports medicine literature as substances that have been used outside regulated channels and are subject to anti‑doping scrutiny. [S2] [S3] [S6]
Uses discussed in research
Reported uses in the reviewed literature are principally experimental: preclinical tendon repair models (e.g., Achilles tendon repair in rats), in‑vitro wound‑healing and cytotoxicity assays, and analytical detection studies for doping control and research. [S7] [S4] [S8] [S6]
Analytical detection studies have focused on identifying TB‑500 (N‑acetylated LKKTETQ) and its metabolites in biological matrices (plasma, urine) and validating chromatographic‑mass spectrometric methods to detect prior administration in animals used in sport. [S8] [S4] [S6]
Mechanisms discussed in published studies
Mechanistic statements in reviews and analytical reports link the active peptide region to actin binding and to cellular behaviors central to wound repair (cell migration, angiogenesis, and collagen deposition), and more general peptide literature situates wound‑healing peptides in pathways controlling angiogenesis and extracellular matrix remodeling. [S8] [S4] [S1]
Broader peptide reviews note that therapeutic peptides can act on molecular signaling networks relevant to tissue regeneration (e.g., PI3K/Akt, mTOR, MAPK, TGF‑β, AMPK), but direct, detailed mechanistic attribution of those specific intracellular pathways to TB‑500 in humans is not established in the reviewed excerpts. [S1]
Metabolism data indicate that TB‑500 is processed to smaller peptide fragments in serum and urine and that some metabolites persist longer (for example Ac‑LKK detected up to ~72 hours in one rat study) and may contribute to measurable wound‑healing activity in vitro. [S4]
Reported study designs and protocol examples
Examples of reported experimental designs in the reviewed sources include: (a) a randomized rat Achilles tendon transection and repair study comparing control, BPC‑157, TB‑500, and combination groups with daily intraperitoneal dosing for four weeks and multimodal outcome assessment (biomechanical testing and histology); (b) in‑vitro enzyme and human serum metabolic studies with fibroblast wound‑healing assays; and (c) LC‑MS/MS and UHPLC‑Orbitrap analytical detection studies in animal plasma and urine to identify parent peptide and metabolites. [S7] [S4] [S8] [S6]
Reviews of the field emphasize that clinical dosing regimens, frequency, and duration for human therapeutic use have not been established in the peer‑reviewed clinical literature. [S2] [S3]
Protocol table from cited sources
The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.
| Source | Study Type | Model / Subject | Amount Reported | Route Reported | Frequency | Duration | Notes |
|---|---|---|---|---|---|---|---|
| [S7] | Journal Article | Male Sprague‑Dawley rats (12 weeks, ~330 g) | TB-500: 60 µg/kg/day | Intraperitoneal | Daily | 4 weeks | Standardized Achilles tendon transection and repair; comparison groups included control, BPC‑157 (10 µg/kg/day), TB‑500 (60 µg/kg/day), and combined BPC‑157 + TB‑500; outcomes: maximum load to failure, histological and immunohistochemical assessments (Bonar and Movin scoring, collagen analyses). |
| [S4] | Journal Article (analytical and in‑vitro study) | In‑vitro enzyme systems, human serum, and rats | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | Developed and validated UHPLC‑Q‑Exactive orbitrap MS method to quantify TB‑500 and metabolites; identified Ac‑LK as primary metabolite at 0–6 h and Ac‑LKK as a longer‑lived metabolite up to ~72 h; no cytotoxicity of parent or metabolites in fibroblasts; Ac‑LKKTE showed significant wound‑healing activity in fibroblast assays. |
| [S8] | Journal Article (analytical/doping control in equine) | Horses (equine samples) | 10 mg (single dose reported in study for detection validation) | not reported in the reviewed source | Single dose | Not applicable for single‑dose detection; analyte detectable in plasma/urine at low ng/mL levels per method validation | Solid‑phase extraction with ion‑exchange cartridges and LC/MS used to detect N‑acetylated LKKTETQ and metabolites in equine plasma and urine; method sensitivity reported (0.02 ng/mL in plasma, 0.01 ng/mL in urine). |
Limitations and research gaps
- Human clinical trial data and systematic safety evidence for TB‑500 are lacking in the reviewed sources; most evidence is preclinical, analytical, or from animal models.
- Dosing, frequency, route, and duration for human therapeutic use are not established in the reviewed literature.
- Metabolism data indicate active metabolites may contribute to observed effects, leaving uncertainty about the relative roles of parent peptide versus metabolites.
- TB‑500 and related thymosin β4 preparations have been discussed in contexts subject to anti‑doping regulation and may be used outside regulatory oversight.
Documentation checklist
- Identify whether a peer‑reviewed human clinical trial exists for the intended indication (none reported in reviewed sources).
- Confirm analytical identity and purity using validated reference standards and appropriate LC‑MS methods before any research application.
- Review regulatory and anti‑doping status for TB‑500 in relevant jurisdictions and sporting bodies.
- Interpret preclinical efficacy signals as preliminary and not equivalent to established clinical benefit.
Related research supplies
- UHPLC‑Q‑Exactive Orbitrap mass spectrometer (analytical platform referenced in metabolism study)
- LC‑MS consumables and columns (for peptide detection and quantification)
- Solid‑phase extraction ion‑exchange cartridges (used in equine plasma/urine sample preparation)
- Analytical‑grade peptide reference standards (for assay calibration and metabolite identification)
- Cryovials, cold‑storage racks, and inventory labeling supplies (for sample storage and organization)
Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.
Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.
Case with accessory space
Qunclay 14-Slot Vial Travel Case
A 14-slot case with additional compartments that can support organized research-supply storage. Use only for compatible materials and documented workflows.
Electronics and screen care
iCloth 70% IPA Electronics Wipes
Lint-free wipes marketed for compatible screens and electronics, useful in documentation and equipment work areas.
Batch and inventory labeling
Phomemo M110 Label and Barcode Printer
A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.
Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.
Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.
Sources and references
- [S1] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
- [S2] Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.. The American journal of sports medicine. 2026. PMID: 41476424. DOI: 10.1177/03635465251357593
- [S3] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0
- [S4] Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2024. PMID: 38382158. DOI: 10.1016/j.jchromb.2024.124033
- [S5] Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.. Frontiers in aging. 2026. PMID: 42021992. DOI: 10.3389/fragi.2026.1790247
- [S6] Thevis M, Schänzer W. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.. Journal of pharmaceutical and biomedical analysis. 2014. PMID: 24906629. DOI: 10.1016/j.jpba.2014.05.020
- [S7] Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.. Joint diseases and related surgery. 2026. PMID: 42542926. DOI: 10.52312/jdrs.2026.2951
- [S8] Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.. Journal of chromatography. A. 2012. PMID: 23084823. DOI: 10.1016/j.chroma.2012.09.043
Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.